Master protocols in Low-and-Middle income countries: A review of current use, limitations and opportunities for precision medicine
Luke ouma,Sarah Al-Ashmori,Samuel Sarkodie,Lou Whitehead,Ann Breeze Konkoth,Shaun Hiu,Theophile Bigirumurame,Dorcas Kareithi,Jingky Lozano-Kuehne,Marzieh Shahmandi,James M. S Wason
DOI: https://doi.org/10.1101/2024.12.03.24318453
2024-12-05
Abstract:Background: Master protocols - umbrella, basket and platform trials that study multiple therapies, multiple diseases or both, offer many advantages, most profoundly that they answer multiple treatment related questions, that would otherwise take multiple trials. We conducted a review of trial registries to characterise their use in advancing precision medicine in low and middle income countries (LMICs).
Methods: We searched trial records available in 20 trial registries globally, including ClinicalTrials.gov and WHO ICTRP, to identify umbrella, basket and platform trials
launched until 30 September 2023.
Results: We identified 102 master protocols - 29 umbrella trials, 31 basket trials, 36 platform trials, as well as 6 other designs that partially aligned with the working definition of master protocols run in 54 different LMICs. Most trials were pharmaceutical industry-sponsored studies (60/102, 58.8%), conducted in oncology settings (56/102, 54.9%), currently ongoing (69/102, 67.6%) in early phase (phase I and II) settings (70/102, 68.6%). There was a greater representation of upper middle-income countries, particularly China that was a site to more than half of all master protocols (53/102, 52%). Other common countries included Brazil, Russia, Turkey and Argentina. Most master protocols (93/102 91.2%) have been planned or launched in the last five years (2019 onwards), mainly with international collaborations in high-income countries. Only a small proportion of trials (5/102, 4.9%) launched exclusively in LMICs excluding china and European LMICs. For most studies, the statistical aspects of trial design and trial documentation (including study protocols and statistical analysis plans) were not publicly accessible.
Conclusion: Unlike high-income countries, where several hundreds of master protocols are ongoing or completed, there is limited use of master protocols in LMICs, partly
owing to low penetration of precision medicine research and limited clinical trial infrastructure in most LMICs. The evidence presented herein create a case for supporting precision medicine initiatives in LMICs (especially Africa), and training and capacity building initiatives focused on innovative clinical trial designs like master
protocols, especially in therapeutic areas outside oncology.
Public and Global Health